United States: Mallinckrodt Pays $100 Million In One Of FTC's Last Antitrust Actions Of The Obama Administration

On January 18, 2017, the U.S. Federal Trade Commission (FTC) and the Attorneys General of Alaska, Maryland, New York, Texas, and Washington filed a complaint in federal district court for the District of Columbia seeking a permanent injunction and other equitable relief against Mallinckrodt ARD Inc. and Mallinckrodt plc (Mallinckrodt) for unfair methods of competition in violation of Section 5 of the FTC Act and monopolization in violation of Section 2 of the Sherman Act, as well as various state antitrust laws.1Specifically, the FTC alleged that Questcor Pharmaceuticals, Inc. (Questcor), now owned by Mallinckrodt,2 harmed competition by acquiring the U.S. rights to Synacthen Depot (Synacthen), a potential competitor to Questcor's H.P. Acthar Gel product (Acthar).3 Mallinckrodt agreed to settle these charges in exchange for relinquishing its rights to Synacthen for certain medical conditions and for a payment of $100 million in equitable relief plus attorneys' fees.4

The case is noteworthy because, although this settlement was one of the last antitrust actions of the Obama Administration, the reaction of the FTC's lone Republican and now-Acting Chairman provides some guidance as to the FTC's likely approach to equitable monetary relief (i.e., disgorgement and restitution) under the Trump Administration. In this matter, the FTC's theory of harm—the elimination of potential competition in the pharmaceutical industry—is not necessarily groundbreaking, but the type and size of the remedy seem a clear attempt by the FTC to make a statement to dissuade such conduct in the future. This monetary settlement is one of the largest ever received by the FTC in an antitrust case.5 It also marks just the third time since withdrawing its Policy Statement on Monetary Equitable Remedies in Competition Cases (Policy Statement) in 20126 that the FTC has sought and obtained such relief. Because the Complaint was supported by all members of the FTC, parties should be mindful of acquisitions of potential competitors in concentrated industries. However, the Acting Chairman's concurring statement7 suggests that, as a result of the transfer of control of the FTC from the Democrats to Republicans, such monetary remedies may not be common in the next few years.

FTC's Complaint

The FTC's Complaint stated that Acthar is the only therapeutic adrenocorticotropic hormone (ACTH) product sold in the U.S. ACTH is the primary drug used to treat infantile spasms (IS), as well nephrotic syndrome (NS), a kidney disorder caused by idiopathic membranous nephropathy (IMN), among other disorders.8 Acthar was acquired by Questcor from Aventis Pharmaceuticals, Inc. for $100,000 in 2001.9 A synthetic ACTH alternative to Acthar, Synacthen, is used in Europe, Canada, and other parts of the world, but it has not yet received approval from the U.S. Food and Drug Administration for sale in the U.S.10

The FTC alleged that Acthar provided Questcor monopoly power as demonstrated by both direct and indirect evidence.11 As direct evidence, the FTC cites Questcor's ability to increase the price of Acthar from $40 to over $34,000 today (equivalent to an 85,000 percent price increase from 2001 to present).12

The FTC also noted that Questcor has been able to maintain that high price for Acthar even as payors restricted it from their formularies.13 Further, the Complaint stated that other bidders for Synacthen projected that that drug would be offered at a lower price than Acthar's current price, suggesting Acthar is priced at a supracompetitive level.14

As indirect evidence, the FTC alleged that Acthar has a 100 percent share of the market for ACTH drugs in the U.S.15 ACTH drugs are considered without substitute for the vast majority of IS patients and as the last line of defense for the treatment of IMN.16 When pricing Acthar, Questcor does not reference any other drugs used to treat these indications.17

In June 2013, Questcor acquired the exclusive rights to develop, market, and sell Synacthen in the U.S and 35 other countries for as much as $300 million (with $135 million guaranteed).18 The FTC contends the purpose of this acquisition was to prevent direct competition to Acthar from Synacthen, because Questcor had conducted only limited due diligence and had only "inchoate plans for Synacthen[.]"19 To achieve this, Questcor offered a significantly higher guaranteed bid than any other potential licensee.20

The Complaint stated that Questcor repeatedly concluded that Synacthen posed a competitive threat to its Acthar monopoly, and that other bidders had business plans and regulatory approval strategies to develop Synacthen to compete with Questcor.21 By acquiring Synacthen, the FTC claimed that Questcor "thwarted a nascent challenge to its Acthar monopoly and thereby harmed competition."22 Questcor claimed that it acquired Synacthen to develop the drug for new, non-Acthar indications, but the FTC suggested this was pretextual and that Questcor could have pursued these new indications using Acthar given the similarities between the drugs.23

The Settlement

To settle these charges, Mallinckrodt agreed to a stipulated order in which it is required to grant a sublicense to Marathon Pharmaceuticals, LLC (Marathon) with all rights necessary to allow Marathon to develop Synacthen for the treatment of IS and NS.24 However, Mallinckrodt will retain the rights to Synacthen to develop the drug for the treatment of another condition, Duchenne Muscular Dystrophy.25 The sublicense will be offered at no minimum price and on terms and conditions approved by the FTC within 120 days after entry of the order by the court.26 Mallinckrodt also agreed to other terms to ensure the successful transfer of the Synacthen rights, as well as to provide prior notification to the FTC if it attempts to develop or acquire rights to a synthetic ACTH product in the future.27

In addition, Mallinckrodt is required to pay $100 million in equitable relief, as well as $2 million in attorneys' fees to the state attorney general plaintiffs.28 Since the FTC withdrew its Policy Statement in 2012, it has settled only two other antitrust matters with large sums of equitable monetary relief.29 That statement previously required that to seek disgorgement, the FTC must: (1) find a clear violation of the antitrust laws, (2) have a reasonable basis for calculating a monetary equitable remedy, and (3) find that other remedies are likely to fail to accomplish fully the purposes of the antitrust laws or when such a monetary remedy otherwise may provide important additional benefits to non-monetary relief.30

Concurring Statement of Acting Chairman Maureen K. Ohlhausen

The Commission voted 3-0 in favor of issuing the Complaint and accepting the Settlement, but Acting Chairman Maureen K. Ohlhausen, the only Republican currently on the Commission, authored a concurring statement.31 In that statement, Acting Chairman Ohlhausen noted that she agreed Questcor's conduct was unlawful, and the licensing remedy was necessary to restore competition, but she expressed concerns about the equitable monetary relief obtained here.32

Acting Chairman Ohlhausen's concerns stemmed from the fact this action did not meet the standard for disgorgement set forth in the FTC's now-withdrawn Policy Statement, the withdrawal of which she opposed in 2012.33 Acting Chairman Ohlhausen did not provide details as to why this action failed to meet that standard, but did say she would have preferred to settle this case in the FTC's administrative process instead (where monetary equitable relief would not have been available).34


The FTC's action should be a reminder that the agency is particularly focused on competition issues in the pharmaceutical industry. Given the FTC's focus in this action on Questcor's price increases, pharmaceutical companies must be careful when pricing their products. If a product is faced with few competitive alternatives, parties should be particularly mindful of acquisitions that could be construed to eliminate either current or future competition. Further, the bipartisan support for the FTC's Complaint suggests that parties will need to be cautious of this type of behavior in the future.

However, the Acting Chairman's opposition to the equitable monetary relief suggests that the FTC is unlikely to seek such remedies in competition cases under the Trump administration. Her consistent opposition to monetary relief—both in her initial opposition to the 2012 withdrawal of the FTC's Policy Statement and her continued opposition in this matter—suggests these disgorgement actions may be less common under the new Administration.


1. Complaint, FTC, et al. v. Mallinckrodt ARD Inc. and Mallinckrodt plc, No. 1:17-cv-00120 (D.D.C. Jan. 18, 2017) (hereinafter, "Complaint").

2. Questcor is now known as Mallinckrodt ARD Inc.

3. Complaint at 3.

4. Proposed Stipulated Order for Permanent Injunction and Equitable Monetary Relief, FTC, et al. v. Mallinckrodt ARD Inc. and Mallinckrodt plc, No. 1:17-cv-00120 (D.D.C. Jan. 18, 2017) (hereinafter, the "Settlement").

5. It ties the FTC's 2000 settlement with Mylan Laboratories, Inc. as the FTC's second largest monetary relief received in an antitrust case. See Order and Stipulated Permanent Injunction, FTC v. Mylan Laboratories, Inc., et al., No. 1:98-cv-03114 (TFH) (D.D.C. Nov. 29, 2000). The largest antitrust case settlement is the FTC's $1.2 billion settlement with Cephalon, Inc. and Teva Pharmaceutical Industries, Ltd. in 2015. Stipulated Order for Permanent Injunction and Equitable Monetary Relief, FTC v. Cephalon, Inc., No. 2:08-cv-2141 (E.D. Pa. Jun. 17, 2015).

6. See Statement of the Commission, Withdrawal of the Commission's Policy Statement on Monetary Equitable Remedies in Competition Cases (Jul. 31, 2012).

7. Concurring Statement of Commissioner Maureen K. Ohlhausen, In the Matter of Mallinckrodt ARD Inc., File No. 131-0172 (Jan. 18, 2017) ("Ohlhausen Statement"). President Donald J. Trump designated Maureen K. Ohlhausen as Acting Chairman of the FTC on January 25, 2017.

8. Complaint at 2.

9. Id.

10. Id. at 2-3.

11. Id. at 5.

12. Id. at 5-6.

13. Id. at 6.

14. Id.

15. Id. at 8.

16. Id. at 6-7.

17. Id. at 6.

18. Id. at 11.

19. Id.

20. Id. at 8.

21. Id. at 9-10.

22. Id. at 12.

23. Id.

24. Joint Motion for Entry of Stipulated Order for Permanent Injunction and Equitable Monetary Relief, No. 1:17-cv-00120, at 3 (D.D.C. Jan. 18, 2017) (hereinafter, "Joint Motion").

25. Id.

26. Settlement at 10-11.

27. Id. at 11-16.

28. Id. at 16-18.

29. The first was a $26.8 million settlement with Cardinal Health, Inc. in 2015, which settled charges that Cardinal Health, Inc. monopolized 25 local markets for the sale and distribution of low-energy radiopharmaceuticals. Final Order and Stipulated Permanent Injunction, FTC v. Cardinal Health Inc., No. 15-cv-3031 (ER) (Apr. 23, 2015). The second was the $1.2 billion Cephalon settlement, also in 2015, relating to allegations Cephalon, Inc. monopolized the market for the sale of its sleep-disorder drug, Provigil. See Statement of the Federal Trade Commission, FTC v. Cephalon, Inc. (May 28, 2015).

30. See Fed. Trade Comm'n, Policy Statement on Monetary Equitable Remedies in Competition Cases, 68 Fed. Reg. 45820 (Aug. 4, 2003).

31. See Ohlhausen Statement.

32. Id. at 1.

33. Id.; see Statement of Commissioner Maureen K. Ohlhausen Dissenting from the Commission's Decision to Withdraw its Policy Statement on Monetary Equitable Remedies in Competition Cases (Jul. 31, 2012).

34. Ohlhausen Statement at 2.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.